Holen Sie sich die Stockscreener-App
1.82
0.55%
-0.01
Schlusskurs vom Vortag:
$1.83
Offen:
$1.82
24-Stunden-Volumen:
412.68K
Relative Volume:
0.43
Marktkapitalisierung:
$121.92M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-122.44M
KGV:
-0.8075
EPS:
-2.254
Netto-Cashflow:
$-103.79M
1W Leistung:
-0.27%
1M Leistung:
+1.68%
6M Leistung:
-81.31%
1J Leistung:
-63.60%
1-Tages-Spanne:
$1.78
$1.835
1-Wochen-Bereich:
$1.78
$1.9188
52-Wochen-Spanne:
$1.40
$12.25
Engene Therapeutics Inc Stock (ENGN) Company Profile
Firmenname
Engene Therapeutics Inc
Sektor
Branche
Telefon
(514) 332-4888
Adresse
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Compare ENGN vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENGN
Engene Therapeutics Inc
|
1.82 | 118.57M | 0 | -122.44M | -103.79M | -2.254 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Engene Therapeutics Inc Stock (ENGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Eingeleitet | WBB Securities | Buy |
| 2026-01-30 | Eingeleitet | Jefferies | Buy |
| 2025-11-11 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-02-18 | Eingeleitet | Piper Sandler | Overweight |
| 2025-02-14 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-27 | Eingeleitet | Raymond James | Outperform |
| 2024-11-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-08-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-22 | Eingeleitet | Wells Fargo | Overweight |
| 2024-04-15 | Eingeleitet | Guggenheim | Buy |
| 2024-03-28 | Eingeleitet | UBS | Buy |
| 2024-03-08 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Engene Therapeutics Inc Aktie (ENGN) Neueste Nachrichten
Deep Track Capital Exits enGene Therapeutics (ENGN) Stake in Sec - GuruFocus
enGene Therapeutics Inc. Stock 12‑Month Price Target Cut to $3.43, Implies 102% Upside - TradingView
enGene (NASDAQ:ENGN) Raised to "Sell" at Wall Street Zen - MarketBeat
Perceptive Advisors (NASDAQ: ENGN) discloses 9.99% beneficial stake with warrant cap - Stock Titan
enGene Holdings (ENGN): Venrock investor group reports 0.0% stake and no voting power - Stock Titan
Deep Track exits enGene Therapeutics (ENGN) position, reports 0% ownership - Stock Titan
Raymond Debbane (ENGN) discloses 9.3% enGene stake via Invus and Avicenna - Stock Titan
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market - MarketBeat
Blue Owl Capital Holdings (ENGN) discloses 0.76% warrant-based stake in enGene - Stock Titan
enGene Therapeutics Inc. (S0N0.F) analyst ratings, estimates and forecasts - uk.finance.yahoo.com
enGene highlights detalimogene NMIBC KOL insights and outlook - TipRanks
enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder CancerSlideshow (NASDAQ:ENGN) 2026-08-11 - Seeking Alpha
enGene Therapeutics Inc.Common Stock (ENGN) Stock Price, News, Quote & History - FinancialContent
enGene Holdings Inc (ENGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
enGene Therapeutics Inc. (S0N0.F) Latest Press Releases & Corporate News - Yahoo! Finance Canada
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026 - Business Wire
enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Rating of "Hold" by Analysts - MarketBeat
enGene Therapeutics Inc. Revenue Breakdown – BOATS:ENGNW - TradingView
enGene (NASDAQ:ENGN) Downgraded to "Strong Sell" Rating by Wall Street Zen - MarketBeat
enGene Therapeutics Inc. Revenue Breakdown – NASDAQ:ENGN - TradingView
Siren L.L.C. Has $35.77 Million Stake in enGene Holdings Inc. $ENGN - MarketBeat
Executive options at enGene Therapeutics (ENGN) vesting over 4 years - Stock Titan
enGene Therapeutics (NASDAQ: ENGN) outlines insider RSUs and options - Stock Titan
enGene Therapeutics (ENGN) sees 5.0% beneficial stake reported by Acorn group - Stock Titan
enGene Holdings appoints new chairman to guide growth - The Globe and Mail
enGene Highlights Progress of Lead Bladder Cancer Therapy - TipRanks
enGene Therapeutics (NASDAQ: ENGN) posts 54% response in NMIBC study - Stock Titan
EnGene Therapeutics (ENGN) price target decreased by 64.55% to 8.72 - MSN
enGene Therapeutics announces board changes - The Pharma Letter
enGene names Michael Heffernan board chairman as Richard Glickman steps down - Bitget
enGene Updates Corporate Presentation, Says Pivotal LEGEND 12‑Month Data and BLA Filing Expected 2H 2026 - TradingView
enGene appoints Michael Heffernan as board chairman By Investing.com - Investing.com Australia
enGene appoints Michael Heffernan as board chairman - Investing.com
Dr. Richard Glickman resigns as chairman of enGene Therapeutics - TradingView
enGene Therapeutics (Nasdaq: ENGN) names new chair, plans BLA filing - Stock Titan
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones - Business Wire
Bronstein, Gewirtz & Grossman, LLC Encourages enGene Therapeutics - The National Law Review
enGene Therapeutics (ENGN) JMP Hematology and Oncology Summit 2024 Summary - Quartr
enGene reports 54% response rate in bladder cancer trial - Investing.com
Piper Sandler downgrades enGene Therapeutics (ENGN) - MSN
enGene Therapeutics Inc. Actuals & Estimates (NASDAQ:ENGN) - TradingView
enGene Therapeutics Inc. Financial Disclosures & Filings - TradingView
Enterprise value to EBITDA forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
Enterprise value to revenue forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
ENGNenGene Therapeutics Inc Volatility & Greeks - Finviz
Price to earnings forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
Enterprise value to EBIT forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
Price to sales forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
enGene Therapeutics Inc. Actuals & Estimates (FWB:S0N0) - TradingView
Layoff Tracker: Biogen axes ‘small number’ of Apellis roles after $5.6B buy - BioSpace
Finanzdaten der Engene Therapeutics Inc-Aktie (ENGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):